Phase I study of single-dose BMY-28100, a new oral cephalosporin.

The objective of this Phase I study was to evaluate the safety, tolerance, and pharmacokinetics of BMY-28100 in 36 male subjects after the administration of single oral doses of 250, 500, and 1,000 mg. The subjects were divided into groups of 12 per dose group. All subjects completed the study, and...

詳細記述

書誌詳細

出版年:	Antimicrob Agents Chemother
主要な著者:	Barbhaiya, R H, Gleason, C R, Shyu, W C, Wilber, R B, Martin, R R, Pittman, K A
フォーマット:	Artigo
言語:	Inglês
出版事項:	American Society for Microbiology (ASM) 1990
主題:	Research Article
オンライン･アクセス:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC171556/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2327766/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.34.2.202
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!